Due to stability concerns, the National Agency for Food and Drug Administration and Control (NAFDAC) has discontinued the registration of Multi-Dose Anti-Malarial (Artemether/Lumefantrine) dry powder for oral suspension.
This decision affects all locally manufactured and imported products, and NAFDAC will no longer accept new applications, renewals, or variations for this product.
The announcement was made in a public alert No. 01/2025, released on the agency’s website…
Read the full article here
